Analysts think CTMX stock price could increase by 117%
Mar 09, 2026, 11:26 AM
-0.53%
What does CTMX do
CytomX Therapeutics, a clinical-stage biopharmaceutical company based in South San Francisco, develops conditionally activated biologics for oncology, with a pipeline including CX-904 and CX-2051. The company went public on October 8, 2015, and has 120 employees.
11 analysts think CTMX stock price will increase by 117.48%. The current median analyst target is $10.20 compared to a current stock price of $4.69. The lowest analysts target is $6.06 and the highest analyst target is $10.50.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.